Veeva Systems (NYSE:VEEV) today announced four of the worlds top seven largest CROs are standardizing on Veeva Vault eTMF. These leading CROs have selected Vault eTMF to improve trial efficiency, give sponsors full visibility into TMF status, and ensure their TMFs are always inspection ready.
CROs are taking steps to modernize their clinical operations to drive more efficient trials, said Jim Reilly, vice president of Veeva Vault Clinical. Our goal is to make it easier for CROs to work with sponsors and sites and accelerate drug development. Were honored to support CROs mission to speed study execution and get treatments to patients faster.
CROs are adopting Vault eTMF to improve operational performance and deliver greater transparency into TMF quality. Vault eTMF manages all TMF documents and processes in one system, in real-time, as they are executed. This active TMF operating model enables CROs to maintain an always up-to-date TMF and gives sponsors greater control of standard operating procedures for TMF management.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
For more information on Veeva Vault eTMF, visit: veeva.com/eTMF
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Vault Clinical Suite
Veeva Vault eTMF is part of the Veeva Vault Clinical Suite, the industrys first cloud platform that includes CDMS, CTMS, eTMF, and study start-up to unify clinical data management and clinical operations. Veevas suite of unified applications provides global visibility into trial activities and streamlines end-to-end clinical processes. For more information, visit veeva.com/Clinical.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 675 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
This release contains forward-looking statements, including the market demand for and acceptance of Veevas products and services, the results from use of Veevas products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veevas historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veevas expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veevas financial results are included under the captions, Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations, in the companys filing on Form 10-Q for the period ended October 31, 2018. This is available on the companys website at veeva.com under the Investors section and on the SECs website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.